Aratana Therapeutics, which is developing medications for cats and dogs based on therapies for humans, raised $35 million by offering 5.8 million shares, 250,000 more than anticipated, at $6, in line with the lower revised price. The company had previously filed to offer 4.3 million shares at a range of $11 to $13 before cutting the deal size Wednesday morning. Aratana Therapeutics will list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets acted as lead managers on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
